Clinical trial
A Single-arm, International, Prospective, Interventional, Open-label, Multicenter Study of Radium-223 Dichloride in the Treatment of Patients With Castration-Resistant Prostate Cancer (CRPC) With Bone Metastasis.
NCT01810770 is registered in ClinicalTrials.gov with Bayer as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Single-arm, International, Prospective, Interventional, Open-label, Multicenter Study of Radium-223 Dichloride in the Treatment of Patients With Castration-Resistant Prostate Cancer (CRPC) With Bone Metastasis.
- Lead sponsor
- Bayer
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- March 26, 2013
- Completion date
- September 25, 2017
- Enrollment
- 243 (actual)
- Sites
- 27
Conditions
As the registry lists them; a condition with its own page is linked.